Clinical trial · Interventional
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
A Phase I Study of BMS-354825 in Patients With Solid Tumors
NCT00339144CI-TRIAL-00004196completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Dasatinib (100 mg)
- interventionNames
- Drug: Dasatinib
- type
- EXPERIMENTAL
- label
- Dasatinib (150 mg)
- interventionNames
- Drug: Dasatinib
- type
- EXPERIMENTAL
- label
- Dasatinib (200 mg)
- interventionNames
- Drug: Dasatinib
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD) and Maximum Acceptable Dose (MAD) of Dasatinib as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to Dasatinib Treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2 * Histologic or cytologic diagnosis of a solid tumor which has progressed on or following standard therapies (including relapsed disease) or for which no standard therapy exists. * men and women, ages 20 and over * women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized * Adequate hepatic function Exclusion Criteria: * Participants who are eligible and willing to undergo transplantation at pre- study. * Women who are pregnant or breastfeeding with known brain metastasis or symptoms of brain metastasis * Uncontrolled or significant bleeding disorder unrelated to a primary tumor * Dementia or mental illness that would prohibit understanding or giving informed consent. * Severe allergy to drugs required for appropriate supportive care of patients in this study. * History of gastrointestinal surgery or of any digestive disorder which has the potential to inhibit absorption of the study drug. * Pleural effusion \> Grade 1 * Patient with dysphagia * Does not agree to blood/blood products transfusion(s) * Donated blood over 200 mL within 4 weeks prior to the start of study therapy * Medication that known to have a risk of causing Torsade de pointes * Participants who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
References
Publications (0)
Data not yet available
No reference posted for this study.